Dr. Jason Robert Guertin is a researcher at the Centre de recherche du CHU de Québec – Laval University and an assistant professor in the Department of Preventive and Social Medicine of Université Laval’s Faculty of Medicine.

Financial evaluation is a pivotal component of health technology assessment. It aims to support decision-makers to establish if adopting a novel health technology represents the most efficient use of available resources. Considering that healthcare demands are continuously on the rise, and budgets are overstretched, many health technology assessment units in Canada and abroad are examining the option of reassessing the value of previously adopted technologies using observational economic revaluations. Dr. Guertin’s research program focuses on the various components of economic evaluations and revaluations conducted within an observational setting. More recently, his work has focused on: 1) the development of novel methods aimed at addressing limits associated with observational economic evaluations; 2) evaluating the impact of chronic diseases on patients’ health-related quality of life in Quebec and Canada; and 3) the economic evaluation of health technologies in the field of personalized medicine.

Hôpital Saint-Sacrement
1050 Chemin Sainte-Foy
J1-09B
Québec, QC
Canada G1S 4L8
+1 418-525-4444, extension 82516
jason-robert.guertin@crch... jason.guertin@fmed.ulaval...

Latest news

95 entries « ‹ 10 of 10 › »

Sas G, Boothroyd LJ, Guertin JR, Lambert LJ, Morin JE, Chakor H, Bogaty P

Évaluation des données probantes sur les dispositifs d'assistance ventriculaire gauche HeartMate II et HeartWare pour le traitement de l'insuffisance cardiaque chronique terminale : avis

Book

Institut national d’excellence en santé et en services sociaux (INESSS), Québec, QC, 2012, ISBN: 9782550660378.

Guertin JR, Dorais M, Khairy P, Sauriol L, Matteau A, Poulin F, Talajic M, Roy D, LeLorier J

Atrial fibrillation: a real-life observational study in the Québec population

Journal Article

Can J Cardiol, 27 (6), 2011.

Abstract | Links:

Guertin JR, Jackevicius CA, Cox JL, Humphries K, Pilote L, So DY, Tu JV, Wijeysundera H, Rinfret S,

The potential economic impact of restricted access to angiotensin-receptor blockers

Journal Article

CMAJ, 183 (3), 2011.

Abstract | Links:

Guertin JR, Liu A, Abrahamowicz M, Cohen DJ, Ismail S, LeLorier J, Brophy JM, Rinfret S

Willingness to pay to eliminate the risk of restenosis following percutaneous coronary intervention: a contingent valuation

Journal Article

Circ Cardiovasc Qual Outcomes, 4 (1), 2011.

Abstract | Links:

Nowakowska D, Guertin JR, Liu A, Abrahamowicz M, Lelorier J, Lesperance F, Brophy JM, Rinfret S

Analysis of willingness to pay for implantable cardioverter-defibrillator therapy

Journal Article

Am J Cardiol, 107 (3), 2011.

Abstract | Links:

95 entries « ‹ 10 of 10 › »
Signaler des ajouts ou des modifications

Active projects

  • A multicenter skin research group focusing on novel treatment for epidermolysis, from 2022-12-01 to 2025-02-28
  • Coûts des maladies cardiovasculaires et des problèmes de santé mentale attribuables aux contraintes psychosociales au travail : Une étude longitudinale de 22 ans auprès de 9 000 cols blancs., from 2016-07-01 to 2025-03-31
  • Création d’une macro standardisée et validée permettant l’ajustement pour l’inflation des données économiques comprises dans les données médico-administratives, from 2022-08-01 to 2025-03-31
  • Enjeux et défis de la mise en œuvre de la thérapie assistée par psilocybineau CHU de Québec – Université Laval : Une étude de cas, from 2024-09-10 to 2025-08-31
  • GMEB-SASS: The first clinical trial phase I/II using a genetically modified epidermolysis bullosa self-assembled skin substitute to treat dystrophic epidermolysis bullosa, a severe rare skin disease, from 2024-04-01 to 2028-03-31
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2025-03-31
  • Projet BEST - Vers l’amélioration du Bien-Être et de la Santé au Travail (BEST) du personnel de la santé et des services sociaux (Budget ULaval), from 2024-07-01 to 2027-06-30
  • Projet BEST - Vers l’amélioration du Bien-Être et de la Santé au Travail (BEST) du personnel de la santé et des services sociaux (Budget UQAR), from 2024-07-01 to 2027-06-30
  • Rapid whole-genome sequencing in acute care neonates and infants, from 2021-07-01 to 2025-09-30
  • Rapid whole-genome sequencing in acute care neonates and infants (gestion éthique), from 2021-07-01 to 2025-09-30
  • Real World Clinical and Economic Burden of Severe Burn Injuries, from 2023-10-01 to 2026-09-30
  • Real World Clinical and Economic Burden of Severe Burn Injuries, from 2023-02-06 to 2025-02-05
  • Reducing low-value practices in acute trauma care: a pragmatic cluster randomized controlled trial, from 2023-04-01 to 2027-03-31
  • Réseaux thématiques - Réseau de thérapie cellulaire, tissulaire et génique du Québec (ThéCell), from 2023-04-01 to 2025-03-31
  • Soutenir l'utilisation d'une approche par cycle de vie au sein d'évaluations économiques en médecine régénératrice, from 2023-07-01 to 2027-06-30
  • Supporting the use of early economic evaluations within the regenerative medicine field, from 2023-04-01 to 2025-01-31
  • The right care, for the right patient, at the right time, by the right provider: A value-based comparison of the management of ambulatory respiratory diseases in walk-in clinics, primary care physician practices and emergency departments, from 2021-10-01 to 2025-03-31

Recently finished projects

  • Adaptation of a standardized self-reported cost questionnaire specific for the severe burn injury population (BI-CoPaQ), from 2022-10-18 to 2023-10-17
  • Audit & Feedback Module Targeting Low-Value Clinical Practices in Injury Care: an Economic Evaluation, from 2020-04-01 to 2023-03-31
  • Clinical validity and clinical utility of a screening test for Paget's disease of bone, from 2019-03-01 to 2023-03-31
  • Création d’une macro automatisée permettant d’estimer les coûts engendrés par des patients au sein des bases de données médico-administratives du Québec., from 2023-10-01 to 2024-09-30
  • Étude de l'éco-efficience du port de l'équipement de protection individuelle contre la COVID-19 dans les urgences pour un contexte post-pandémique, from 2021-10-01 to 2024-03-31
  • Étude préclinique et pharmacoépidémiologique de l’impact du dutastéride dans l’étiopathogenèse et la progression de la maladie de Parkinson, from 2021-04-01 to 2023-08-31
  • Infrastructure de l'évaluation économique en médecine régénératrice, from 2020-04-01 to 2023-03-31
  • Optimisation des approches méthodologiques utilisées dans le cadre d’évaluations économiques basées sur des données observationnelles, from 2019-07-01 to 2023-06-30
  • Optimisation des approches méthodologiques utilisées dans le cadre d’évaluations économiques basées sur des données observationnelles, from 2019-07-01 to 2023-06-30
  • PEGASUS-2 - PErsonalized Genomics for prenatal Abnormalities Screening USing maternal blood : Towards First Tier Screening and Beyond, from 2018-04-01 to 2024-06-30
  • Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente, from 2020-04-01 to 2023-10-27
  • Real-World Evaluation of the Efficacy, Safety and Cost-Effectiveness of Statins for Primary Prevention of Cardiovascular Disease Among the Elderly – A Causal Perspective to Treatment Trajectory Analysis, from 2019-10-01 to 2023-03-31
  • The right care, for the right patient, at the right time, by the right provider: A value-based comparison of the management of ambulatory respiratory diseases in walk-in clinics, primary care physician practices and emergency departments, from 2020-04-01 to 2024-03-31
Data provided by the Université Laval research projects registery